{
    "clinical_study": {
        "@rank": "68820", 
        "arm_group": [
            {
                "arm_group_label": "SSP-004184AQ (single dose)", 
                "arm_group_type": "Experimental", 
                "description": "40 mg/kg (oral capsule form) given once on Day 1"
            }, 
            {
                "arm_group_label": "SSP-004184SS (single dose)", 
                "arm_group_type": "Experimental", 
                "description": "21.8 mg/kg (oral capsule form) given once on Day 1"
            }, 
            {
                "arm_group_label": "SSP-004184AQ (2 doses)", 
                "arm_group_type": "Experimental", 
                "description": "40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1"
            }, 
            {
                "arm_group_label": "SSP-004184SS (2 doses)", 
                "arm_group_type": "Experimental", 
                "description": "21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the relative bioavailability of the new SSP-004184SS capsule\n      formulation compared to the original SSP-004184AQ drug plus excipients formulation."
        }, 
        "brief_title": "A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65 years\n\n          -  Must be considered \"healthy\".\n\n          -  Serum ferritin >20ng/mL, hemoglobin >125g/L and erythrocyte indices within normal\n             range\n\n        Exclusion Criteria:\n\n          -  Subject has a clinically significant history or a disorder detected during the\n             medical interview/physical examination at the Screening Visit or any other medical\n             condition that is capable of altering the absorption, metabolism, or elimination of\n             drugs\n\n          -  Acute illness, as judged by the investigator, within 2 weeks of Day 1 of Treatment\n             Period 1.\n\n          -  Known or suspected intolerance or hypersensitivity to the investigational products,\n             closely related compounds, or any of the stated ingredients.\n\n          -  Subject has a history of thyroid disorder that has not been stabilized on thyroid\n             medication or treatment within 3 months\n\n          -  History of alcohol or other substance abuse within the last year.\n\n          -  A positive screen for alcohol or drugs of abuse at the Screening Visit.\n\n          -  Confirmed systolic blood pressure >139mmHg or <89mmHg, and diastolic blood pressure\n             >89mmHg or <49mmHg.\n\n          -  Twelve-lead ECG demonstrating QTc >450msec at screening.\n\n          -  Routine consumption of more than 2 units of caffeine per day or subjects who\n             experience caffeine withdrawal headaches.\n\n          -  Male subjects who consume more than 3 units of alcohol per day. Female subjects who\n             consume more than 2 units of alcohol per day.\n\n          -  A positive HIV antibody screen, HBsAg, or HCV antibody screen.\n\n          -  Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing\n             products in any form (eg, gum, patch) within 30 days prior to Day 1 of Treatment\n             Period 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905540", 
            "org_study_id": "SPD602-111"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "SSP-004184AQ (single dose)", 
                    "SSP-004184AQ (2 doses)"
                ], 
                "description": "Magnesium salt", 
                "intervention_name": "SSP-004184AQ", 
                "intervention_type": "Drug", 
                "other_name": "SPD602"
            }, 
            {
                "arm_group_label": [
                    "SSP-004184SS (single dose)", 
                    "SSP-004184SS (2 doses)"
                ], 
                "description": "Disodium salt", 
                "intervention_name": "SSP-004184SS", 
                "intervention_type": "Drug", 
                "other_name": "SPD602"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33014"
                }, 
                "name": "Clinical Pharmacology of Miami"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of SSP-004184AQ (Magnesium Salt) to SSP-004184SS (Disodium Salt) Each Administered as a Single Dose and as Two Doses of SSP-004184 (Free Acid) in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Clinical Pharmacology of Miami", 
            "last_name": "Kenneth Lasseter, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Steady-state Plasma Concentration-time Curve (AUC) of SSP-004184 After One Dose", 
                "safety_issue": "No", 
                "time_frame": "Over 120 hours post-dose"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of SSP-004184 After One Dose", 
                "safety_issue": "No", 
                "time_frame": "Over 120 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Steady-state Plasma Concentration-time Curve (AUC) of SSP-004184 After Two Doses", 
                "safety_issue": "No", 
                "time_frame": "Over 120 hours post-dose"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of SSP-004184 After Two Doses", 
                "safety_issue": "No", 
                "time_frame": "Over 120 hours post-dose"
            }
        ], 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}